非布索坦可以治愈痛风吗？

Can gout be cured? The answer is yes. In February 2009, the US Food and Drug Administration approved febuxostat for the long-term Chemicalbook treatment of patients with gout and hyperuricemia. Antigout Drugs Gout is a heterogeneous group of diseases that are inherited or acquired disorders of reduced uric acid excretion and purine metabolism. Due to the excessive production of uric acid in the body and the reduced clearance ability of the kidneys, uric acid accumulates in the body, leading to the deposition of urate crystals in joints and various organs.

Indications of febuxostat: Febuxostat is a Class A recommendation for the drug treatment of patients with hyperuricemia and gout, which is the first-line drug choice. However, it is not recommended for use in asymptomatic hyperuricemia. Febuxostat is a new generation of xanthine oxidase inhibitor developed by Teijin Corporation of Japan. It is clinically used to treat hyperuricemia (gout). Its structure is completely different from the xanthine oxidase inhibitor drug developed 40 years ago. It is a new and highly efficient non-purine xanthine oxidase selective inhibitor. Xanthine oxidase is the key enzyme that promotes uric acid production. 

Febuxostat can reduce the level of uric acid in the blood of patients with hyperuricemic gout. Clinical studies have shown that Febuxostat is safe and effective. Febuxostat is metabolized by the liver and does not rely on renal excretion. Therefore, there is no need to reduce the dose for patients with moderate to severe hepatic and renal insufficiency. 

Therefore, gout treatment usually involves promoting uric acid excretion and inhibiting uric acid production, and taking appropriate measures to improve related symptoms. The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid. Febuxostat is the world's latest developed new generation of non-purine selective xanthine oxidase inhibitor. It acts highly selectively on this oxidase to reduce the synthesis of uric acid in the body and lower the concentration of uric acid, thereby effectively treating ventilation diseases.

The above are the diseases that our medical companion travel overseas medical consulting service company provides you with that febuxostat can treat. From this point of view, gout can be treated and cured, and patients can buy it with confidence.